Kane, John M., 1945-
John M. Kane
Kane, John M.
VIAF ID: 109751475 (Personal)
Permalink: http://viaf.org/viaf/109751475
Preferred Forms
- 100 0 _ ‡a John M. Kane
- 200 _ | ‡a Kane ‡b John M. ‡f 1945-....
- 100 1 _ ‡a Kane, John M, ‡d 1945-
-
- 100 1 _ ‡a Kane, John M. ‡d 1945-
- 100 1 _ ‡a Kane, John M. ‡d 1945-
- 100 1 _ ‡a Kane, John M. ‡d 1945-...
-
- 100 1 _ ‡a Kane, John M., ‡d 1945-
- 100 1 _ ‡a Kane, John M., ‡d 1945-
4xx's: Alternate Name Forms (3)
5xx's: Related Names (3)
- 510 2 _ ‡a Long Island Jewish Medical Center
- 510 2 _ ‡a Long Island Jewish Medical Center ‡g New York, NY ‡e Affiliation
- 510 2 _ ‡a Satelliten-Symposium Risperdal, New Horizons for the Schizophrenic Patient 1993 Rio de Janeiro
Works
Title | Sources |
---|---|
Adverse effects of psychotropic drugs | |
Design of industrial ventilation systems : how to design, build, or buy industrial ventilation systems ... | |
Drug maintenance strategies in schizophrenia, 1984: | |
Esquizofrenia | |
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy | |
n84045058 | |
The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research | |
Neuroleptikatherapie | |
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia | |
Optimizing pharmacologic treatment of psychotic disorders | |
Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia | |
Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study | |
Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics: A Systematic Review and Pooled, Patient-Level Analysis of 662 Case Reports | |
A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 2: Negative Symptoms in Schizophrenia [Podcast] | |
Patients' Attitudes Towards Telepsychiatry: Results of a Nationwide, Multisite Survey During the COVID-19 Pandemic | |
Patterns of stress in schizophrenia | |
Pharmacotherapy of schizophrenia | |
PM421. Efficacy and safety of brexpiprazole | |
Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study | |
Predicting Early Warning Signs of Psychotic Relapse From Passive Sensing Data: An Approach Using Encoder-Decoder Neural Networks | |
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia | |
Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia | |
Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. | |
Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. | |
Psychological well-being and mental health recovery in the NIMH RAISE early treatment program | |
Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention | |
QT interval duration and dispersion in children and adolescents treated with ziprasidone | |
The QTc interval and its dispersion in patients receiving two atypical antipsychotics | |
The RAISE early treatment program for first-episode psychosis: background, rationale, and study design | |
Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives | |
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers | |
Rapid clozapine titration in treatment-refractory bipolar disorder | |
Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study | |
The relationship between acoustic startle response measures and cognitive functions in Japanese patients with schizophrenia. | |
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders | |
Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop | |
Risk factors for medical deterioration of psychiatric inpatients: opportunities for early recognition and prevention | |
Role of social media and the Internet in pathways to care for adolescents and young adults with psychotic disorders and non-psychotic mood disorders | |
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. | |
SA17. Response to Treatment With Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia. | |
Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies | |
Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics | |
Schizophrenia: mechanism of action of current and novel treatments | |
Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis | |
The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder | |
Serotonin 6 receptor gene and schizophrenia: case-control study and meta-analysis | |
Serotonin in antipsychotic treatment mechanisms and clinical practice | |
Sex differences in frontal lobe white matter microstructure: a DTI study | |
Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. | |
Structural similarity networks predict clinical outcome in early-phase psychosis | |
Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis | |
Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients | |
Suicidality and hospitalization as cause and outcome of pediatric psychiatric emergency room visits. | |
T234. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION: A STUDY-LEVEL META-ANALYSIS AND META-REGRESSION ANALYSIS. | |
Tardive dyskinesia among Chinese and Malay patients with schizophrenia. | |
Tardive dyskinesia and impaired glucose tolerance | |
Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis | |
Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors: A Systematic Review. | |
Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? | |
Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative. | |
Treatment models and designs for intervention research during the psychotic prodrome | |
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. | |
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology | |
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence | |
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia | |
Utilizing Machine Learning on Internet Search Activity to Support the Diagnostic Process and Relapse Detection in Young Individuals With Early Psychosis: Feasibility Study | |
Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis | |
When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature | |
White matter changes associated with antipsychotic treatment in first-episode psychosis | |
Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? | |
The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. | |
ω-3 Polyunsaturated Fatty Acids to Prevent Psychosis: The Importance of Replication Studies. |